Generation of an artificial human B cell line test system using Transpo-mAb™ technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins

Diana Klose1,2, Mira Woitok1,3, Judith Niesen1, Roger R. Beerli4, Rainer Fischer1,3, Stefan Barth2,5, Rolf Fendel1*, Thomas Nachreiner2*

1 Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Aachen, Germany, 2 Department of Experimental Medicine and Immunotherapy, Institute for Applied Medical Engineering, University Hospital RWTH Aachen, Aachen, Germany, 3 Institute of Molecular Biotechnology (Biology VII), RWTH Aachen University, Aachen, Germany, 4 NBE-Therapeutics AG, Basel, Switzerland, 5 South African Research Chair in Cancer Biotechnology, Institute of Infectious Disease and Molecular Medicine (IDM), Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

* These authors contributed equally to this work.

Citation: Klose D, Woitok M, Niesen J, Beerli RR, Grawunder U, Fischer R, et al. (2017) Generation of an artificial human B cell line test system using Transpo-mAb™ technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins. PLoS ONE 12(7): e0180305. https://doi.org/10.1371/journal.pone.0180305

Introduction

B lymphocytes have both antibody-dependent and antibody-independent functions in the humoral immune system. In addition to the production of monoclonal antibodies, B cells release immunomodulatory cytokines and chemokines that influence the behavior of T cells.
and dendritic cells [1]. B cells are also responsible for antigen presentation, the regulation of lymphoid tissue organization, tissue regeneration, and wound healing. The specific function of peripheral B cells varies according to the B cell subset [1]. The dysregulation of B cell processing can contribute to the development of autoimmune diseases, e.g. aberrant receptor editing and deletions in several tolerance checkpoint genes increase the number of autoreactive B cell precursors [2]. Autoreactive B cells are hyperactive, and the secretion of autoreactive antibodies strongly influences the severity of pathogenesis [3–5]. Hyperactive autoreactive B cells also present autoantigens on the cell surface to stimulate pathogenic T cells. The abnormal recognition of autoantigens due to the breakdown of tolerance by autoreactive B and T cells leads to tissue damage [6, 7]. Systemic lupus erythematosus (SLE) is an autoimmune disorder characterized by an elevated autoantibody titer against nuclear proteins and/or DNA. An expanded subset of plasma blasts and plasma cells in the peripheral blood of patients with SLE is responsible for autoantibody secretion [8–10]. The treatment of autoimmune diseases such as SLE usually involves general immunosuppression and/or immunomodulation approaches that restore homeostasis, e.g. immunosuppressive agents such as the anti-malaria drug hydroxychloroquine, or immunomodulatory agents such as glucocorticoids, but these systemic treatments cause off-target effects that disrupt the immunological repertoire [5, 11–13].

Many standard therapeutic approaches for autoimmune diseases also affect healthy immune system cells, but research has focused recently on strategies for the specific elimination of pathogenic cell populations. Antibodies can be used for the targeted treatment of autoimmune diseases and there are four major mechanisms of action: ligand blocking, receptor blocking/modulation, downregulation of cell-surface receptor expression, and the depletion of antigen-presenting cells [14, 15]. Several human and chimeric antibodies have been developed that target receptors on the B cell surface such as CD19, CD20 and CD22, or B cell survival factors such as BAFF/BLYS and APRIL [13, 14, 16]. However, clinical studies have been mostly unsuccessful due to the failure to achieve clinical endpoints (safety and efficacy) or the prevalence of infection complications [17, 18]. The human monoclonal antibody belimumab, recognizing the B cell survival factor BLYS, is the only antibody that has been approved by the US Food and Drug Administration (FDA) for the treatment of SLE [17–20].

An alternative strategy to specifically eliminate autoreactive B cell populations involves the application of recombinant fusion proteins targeting B cells via their antigen-specific B cell receptors (BCRs). The fusion proteins consist of a cell-binding domain (an autoantigen or fragment thereof) fused to a toxin derived from plants or bacteria. This approach is equivalent to the use of immunotoxins, which were developed specifically to target malignant cell populations [21]. The cell-binding ligands in immunotoxins can be receptors, monoclonal antibodies or single chain variable fragments (scFvs). These are fused to a toxic domain such as the modified Pseudomonas aeruginosa exotoxin A (ETA’), only a few molecules of which are needed to inhibit protein synthesis and induce apoptosis [22]. Immunotoxins based on ETA’ kill target cells efficiently, as demonstrated in several clinical trials [23–25]. In a previous study, we demonstrated that the antigen-specific targeting and depletion of a unique human B cell population was possible using an antigen-based ETA’ fusion protein [26]. In this case, the cell-binding domain was an antigen fragment, the well-established tetanus toxoid fragment C (TTC), and the recombinant TTC-ETA’ protein was tested for its ability to selectively bind and kill the murine TTC-reactive hybridoma cell line 5E4 as well as human tetanus-reactive memory B cells [26]. One drawback limiting the therapeutic impact of immunotoxins containing bacterial or plant toxins is their immunogenicity, particularly when repeated administration is necessary. This has been addressed by the development of a new generation of immunotoxins containing human cytolytic enzymes such as the serine protease granzyme B, the ribonuclease angiogenin, or the microtubule-associated protein tau (MAPTau) [21, 27–31]. We have
developed mutated versions of these effector proteins to increase their potency, e.g. the granzyme B point mutant R201K is resistant to the natural granzyme B inhibitor serpin proteinase inhibitor 9 (PI-9), thus increasing its pro-apoptotic effect against target cancer cells [28, 30, 32]. Similarly, the mutated MAPTau protein includes two point mutations (S154K and S204K) at critical serine phosphorylation sites [33]. This non-phosphorylated MAPTau protein binds to microtubules, blocking the assembly and disassembly of the spindle microtubules, again enhancing its pro-apoptotic effects [34, 35]. Such enhanced human effector domains can also be also used to generate novel antigen-based fusion proteins for the antigen-specific elimination of B-cell populations via their unique BCRs.

The species-dependent reactivity of these human enzymes means that the murine TTC-reactive hybridoma cell line 5E4 cannot be used for the in vitro characterization of GrB (R201K)-TTC and TTC-MAPTau fusion proteins. Therefore, an artificial human cellular test system was required for the initial characterization of these proteins in vitro, including specific cell-binding, internalization and cytotoxicity [21, 36]. An alternative to human hybridoma cell lines is the generation of a specific TTC-reactive lymphocytic B cell line using a transposon-based vector system [37–39]. We used a system based on class II DNA cut-and-paste transposons, where the gene of interest is flanked by inverted terminal repeats (ITRs) that are recognized by the transposase [38, 40]. Transposon gene delivery systems have several advantages over viral vectors, including low cost, less innate immunogenicity and the potential to transfer larger DNA sequences [38, 40–42]. The piggyBac transposase is derived from the cabbage looper (Trichoplusia ni) and facilitates the efficient genetic modification of human cells [43–47]. The piggyBac transposase is included in the Transpo-mAb™ platform, which was developed as a mammalian cell display technology [39]. This allows the integration of human immunoglobulin genes into mammalian host cells, resulting in antibody presentation or expression in a soluble form. The transposase system consists of one plasmid encoding the piggyBac transposase and two further vectors, one each for the human antibody heavy chain and light chain variable genes (V_H and V_L), plus in each case an internal ribosomal entry site (IRES) and a selectable marker such as an antibiotic resistance gene or the enhanced green fluorescent protein (eGFP), all flanked by the ITRs [39]. These Transpo-mAb™ vectors were used to generate a stable human lymphocytic cell line presenting a TTC-specific antibody on the surface, i.e. a TTC-specific BCR. The variable chain sequences of the TTC-reactive murine hybridoma antibody 5E4 [48] were transferred into the vectors containing the ITRs. By co-transfection with an expression vector carrying the piggyBac transposase gene (hy-PB), the transposase was transiently expressed resulting in the insertion of the TTC-antibody V_L and V_H sequences randomly into the genome of REH host cells, a human precursor B cell line derived from an acute lymphocytic leukemia patient [49].

Here we describe the generation of a novel transgenic human lymphocytic cell line specific for TTC. The engineered human B cell line was used to demonstrate the receptor-mediated specific cell binding and internalization of TTC-based fusion proteins. We were thus able to demonstrate the specific toxicity of novel antigen-based fusion proteins with human effector domains.

**Materials and methods**

**Cell lines and cell culture**

TTC-reactive 5E4 hybridoma cells (kindly provided by Prof. Dr. M. Shapiro, Rockville, USA) and REH cells were cultured under standard conditions (RPMI 1640 medium + GlutaMax™ including 10% fetal calf serum (FCS), 100 U/ml penicillin, 100 mg/ml streptomycin, at 37°C, 5% CO₂). Transfected TTC-reactive REH cells (ATCC® CRL-8286™) were cultured after...
sorting in RPMI 1640 medium + GlutaMax™, 20% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin, at 37°C, 5% CO₂ for 1 week to stimulate cell proliferation. Afterwards, the transfected REH cells were cultured under standard conditions.

RNA isolation and cDNA synthesis
RNA was isolated from 5E4 hybridoma cells using the M&N NucleoSpin RNA II Kit (Macherey-Nagel, Düren, Germany) according to the manufacturer’s instructions, and the RNA quality was verified by agarose gel electrophoresis. First-strand cDNA was synthesized using the First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Schwerte, Germany) and the oligo(dT) primers provided in the kit with 1 μg of RNA, according to manufacturer’s instructions.

V-gene DNA amplification
The V<sub>H</sub> and V<sub>L</sub> sequences of the TTC-reactive antibody from the murine hybridoma cell line 5E4 were identified by V-gene rescue polymerase chain reaction (PCR) with the primer set described in our earlier report [50]. The V<sub>L</sub> and V<sub>H</sub> sequences were amplified using Phusion high-fidelity DNA polymerase (Thermo Fisher Scientific), 200 nM of each primer and 1 μl of cDNA in a 50-μl reaction volume. After heating the reaction to 98°C for 30 s, we carried out 28 amplification cycles at 98°C for 8 s, 57°C for 10 s, and 72°C for 15 s, then a final extension step at 72°C for 5 min, in a Veriti 96-well thermocycler (Applied Biosystems, Thermo Fisher Scientific). The PCR products were separated by 1.2% (w/v) agarose gel electrophoresis and purified using the M&N Nucleo Extraction Kit II (Macherey-Nagel) according to the manufacturer’s instructions.

Construction of transposase-based vectors
The V<sub>L</sub> and V<sub>H</sub> sequences of the TTC-reactive antibody clone 5E4 were transferred to vector pJET1.2 using the CloneJET PCR Cloning Kit (Thermo Fisher Scientific) according to the manufacturer’s instructions. After the ligation step, the plasmids were introduced into Escherichia coli strain DH5α by heat shock and plasmid DNA was prepared using the M&N NucleoSpin Kit (Machery Nagel). After PCR amplification of the antibody fragments using the primers listed in Table 1, the sequences were transferred to vector pTT5 [51] by ligation at the AgeI/BsiWI (V<sub>L</sub> fragment) or AgeI/SalI (V<sub>H</sub> fragment) sites [52]. The V<sub>L</sub>/V<sub>H</sub> fragments from vectors pTT5-TTC-V<sub>L</sub>/V<sub>H</sub> were then amplified, including the Ig-kappa leader sequence from the pTT5 vector, and transferred to the pPB-EGFP transposase-based vectors [37, 39] using the restriction sites NotI/BstBI (V<sub>L</sub> fragment) or NotI/Nhel (V<sub>H</sub> fragment) in order to generate the final vector pPB-V<sub>L</sub>/V<sub>H</sub>-TTC-EGFP (Fig 1A). Sequencing was carried out on an ABI Prism™ 3730 Genetic Analyzer (Applied Biosystems).

Table 1. Oligonucleotides for PCR amplification.

| Primer                | Sequence                        |
|-----------------------|---------------------------------|
| AgeI-VL-TTC-fwd       | CTTACTAACCAGGTTACATTTCTGACATCCAGATGACTCAG |
| BsiWI-VL-TTC-rev      | TAGTAACCTGTACGTTTAGTTTTCCAAGCTGTCAGCC |
| AgeI-VH-TTC-fwd:      | CTTACTAACCAGGTTACATTTCTGACATCCAGATGACTCAG |
| VH-TTC-Sal-rev        | TAGTAAGTGGAACGCGCTGAGGACCGTGACTGAGG |
| BstBI-LcPpTT5-rev     | TAGTAAGTGGAACGCGCTGAGGACCGTGACTGAGG |
| VH-TTC-Nhel-rev       | CTTACTAGCCGGCCGCCATGGGATGCTAGATCATACCC |
| Notl-leader-fwd       | CTTACTAGCCGGCCGCCATGGGATGCTAGATCATACCC |

https://doi.org/10.1371/journal.pone.0180305.t001
Transfection of REH cells

To generate a human TTC-specific cell line, REH cells were co-transfected with the plasmids pcDNA3.1-hy-mPB and pPB-V\textsubscript{H}-TTC-EGFP. Prior to transfection, 30 μg of the vectors pPB-V\textsubscript{L}-TTC-EGFP and pPB-V\textsubscript{H}-TTC-EGFP, plus 10 μg of pcDNA3.1-hy-mPB, was prepared in 400 μl RPMI 1640 medium without supplements. We then washed 5 x 10\textsuperscript{6} REH cells twice with RPMI 1640 medium without supplements and re-suspended them in 3 ml of the same (pre-warmed) medium. The plasmid DNA mixture was added to 400 μl of cell suspension (1.7 x 10\textsuperscript{6} cells/ml) and transferred into an electroporation cuvette (BioRad, Munich, Germany). Electroporation was carried out using the GenePulser System (BioRad) at 250 V and 950 μF. After 10 min incubation at room temperature, the cells were washed, re-suspended (RPMI 1640 medium + GlutaMax\textsuperscript{™}, 10% FCS, 100 U/ml penicillin, 100 μg/ml streptomycin) and cultivated at 37°C and 5% CO\textsubscript{2}. REH cells were co-transfected in parallel as described above with the pPB-EGFP-LC-Ac10/pPB-EGFP-HC-Ac10 transposon-based expression vectors described earlier [37] to generate a control cell line (mock-reactive REH cells).
Fluorescence activated cell sorting and monitoring of transfected REH cells

Transfected TTC-reactive REH cells were sorted by fluorescence-activated cell sorting (FACS) using the BD Influx cell sorter (BD Bioscience, Franklin Lakes, New Jersey). Positive transfected REH cells express the reporter protein eGFP and the TTC-specific antibody on the cell surface. The antibody-presenting REH cells were distinguished using a TTC-based fusion protein (SNAP-TTC-BG-647) covalently coupled to a benzylguanine modified fluorescent dye [26]. The fluorescence signals of the eGFP reporter protein and the bound SNAP-TTC-BG-647 protein were used to isolate double-positive TTC-reactive REH cells from the cell population. In the case of the mock-transfected REH cells, FACS was carried out using the eGFP signal and the anti-human-Ig-kappa antibody conjugated to PE-Cy7. Double-positive REH cells were cultivated in RPMI 1640 medium (+ GlutaMax™, 20% FCS, 100 U/ml penicillin, 100 mg/ml streptomycin) at 37˚C and 5% CO₂. To monitor the sorted TTC-reactive REH cells, FACS was carried out using the SNAP-TTC-BG-647 protein [26]. Cultured TTC-reactive or mock-transfected REH cells were collected, washed in FACS staining buffer (1x PBS, 5 mM EDTA, 2% v/v FCS) and incubated with 1 μg SNAP-TTC-BG-647 protein or anti-human-Igkappa-PE-Cy7 antibody (diluted 1:200 in FACS staining buffer) for 20 min on ice in the dark. After washing with FACS staining buffer, the fluorescence signal from the bound protein was measured using a FACSVerse™ device (BD Bioscience) to analyze the presentation of BCRs on the cell surface.

Cloning of eukaryotic expression vectors and protein expression

Cytolytic fusion proteins containing granzyme B variant R201K or MAPTau were expressed in HEK 293T cells. The synthetic TTC DNA sequence (GenBank accession no. FJ917402.1) prepared by GeneArt® Gene Synthesis (Thermo Fisher Scientific) was flanked with NotI/SfiI sites. This synthetic TTC DNA sequence was inserted at the same sites in vector pMS [53] to yield final expression plasmids pMS-EGrB(R201K)-TTC and pMS-TTC-MAPTau. The integrity of the vectors was confirmed by DNA sequencing. Human embryonic kidney cells (HEK293T, ATCC, Wesel, Germany, CRL-11268) were cultured under standard conditions RPMI 1640 medium, 10% v/v fetal calf serum (FCS), 100 U/ml penicillin, 100 mg/ml streptomycin, 37˚C, 5% CO₂). 3x10⁵ HEK 293 T cells per well in a 6-well plate were transfected with the expression vectors (pMS-EGrB(R201K)-TTC and pMS-TTC-MAPTau) using Roti®Fect (Carl Roth) according to the manufacturer’s instructions. Transfected cells were cultured with 100 ng/ml Zeocin®® (Invitrogen, Carlsbad, USA) for selection. The supernatant was collected from the transfected HEK293T cells and the proteins were purified by immobilized metal-ion affinity chromatography (IMAC).

Protein purification

Supernatants were collected from transfected HEK 293T cells so that the cytolytic fusion proteins EGrB(R201K)-TTC and TTC-MAPTau, and the mock-proteins EGrB(R201K)-H22 [54] and IL3-MAPTau (kindly provided by Christoph Stein) was purified by immobilized metal-ion affinity chromatography (IMAC) using a nickel-Sepharose (Ni-NTA) Superflow Cartridge (Qiagen, Hilden, Germany) on a ÄKTApurifier system (GE Healthcare, Chicago, Illinois) as previously described [30, 54–56]. The EGrB(R201K)-TTC protein was dialyzed against 20 mM Tris-HCl, 200 mM NaCl (pH 7.4) and the other proteins were dialyzed against PBS using a 6000–8000 Da molecular weight cutoff (MWCO) ZelluTrans dialysis membrane (Carl Roth, Karlsruhe, Germany) and all the proteins were concentrated using 30,000 Da
MWCO Vivaspin columns (GE Healthcare). Purified proteins were separated by SDS-PAGE and visualized by Coomassie Brilliant Blue staining against Color Prestained Protein Standards, Broad Range (New England Biolabs, Ipswich, Massachusetts). Western blot analysis was carried out using an anti-polyhistidine antibody (Thermo Fisher Scientific) diluted 1:5000 in PBS, and a secondary goat anti-mouse IgG (Fc-specific) antibody (Sigma-Aldrich, Munich, Germany) conjugated to alkaline phosphatase (diluted 1:5000 in PBS). The protein concentration in the samples was determined using an AIDA Analyzer (Raytest GmbH, Straubenhardt, Germany) with bovine serum albumin (BSA) as the standard.

**Internalization assay**

Internalization was investigated using the SNAP-TTC-BG-647 protein [26]. TTC-specific REH cells and the control cells were washed with staining buffer (PBS, 2% FCS, 5 mM EDTA) and re-suspended in RPMI 1640 medium + GlutaMax™, 10% FCS, 100 U/ml penicillin and 100 mg/ml streptomycin, including 1 μg SNAP-TTC-BG-647 protein per sample. Per sample, 1 x 10⁵ cells were incubated with the protein at 37˚C or 4˚C for 30–90 min in the dark. Afterwards, the cells were washed with 2 ml PBS to remove unbound protein and then incubated with Hoechst 33342 (4 μg/μl final concentration) for nuclear staining. The stained cells were transferred directly to a microscope slide and visualized by confocal microscopy using a Leica TCS SP8, LAS AF (Leica Microsystems, Wetzlar, Germany). Images were processed using ImageJ 1.50f software (Wayne Rasband, National Institutes of Health, Bethesda, Maryland).

**Enterokinase digest**

The fusion protein EGrB(R201K)-TTC was activated with one unit of recombinant enterokinase (Merck Millipore, Darmstadt, Germany) per 50 μg protein in 2 mM CaCl₂ in Tris-HCl buffer (20 mM Tris-HCl, 200 mM NaCl, pH 7.4) and then incubated for 16 h at 23˚C. The digested GrB(R201K)-TTC protein was exchanged into PBS using a MiniTrap™ G25 desalting column (GE Healthcare) and the activated protein was stored at –20˚C.

**Granzyme B substrate assay**

The enzymatic activity of the GrB(R201K)-TTC fusion protein was determined using a granzyme B substrate assay with 500 ng of the synthetic substrate Ac-IETD-βNA (Calbiochem/Merck, Darmstadt, Germany). Enzyme kinetics was measured for 60 min at 2-min intervals in 96-well plates on an Epoch Microplate Spectrophotometer (BioTek, Bad Friedrichshall, Germany). All measurements were taken in duplicate.

**Binding of recombinant proteins to TTC-reactive human lymphocytic REH cells**

We washed 1–5 x 10⁵ REH cells (TTC⁺ or control) with FACS staining buffer and incubated them with 100 nM of each recombinant protein for 20 min on ice. After washing in FACS staining buffer the cells were pelleted (500 x g, 5 min, 4˚C) and incubated with an anti-polyhistidine antibody conjugated with phycoerythrin (PE) (clone GG11-8F3.5.1, Miltenyi, Bergisch Gladbach, Germany) for 20 min on ice in the dark. After a final washing step, the signal was measured on the FACSVerse™ instrument and analyzed using FACSuite software v1.05.

**Cell viability and apoptosis assays**

An XTT-based cell viability assay was used to determine the toxicity of the TTC-based proteins against the hybridoma cell line 5E4 and human lymphocytic TTC-reactive REH cells. The cells...
(1x10^4 cells per well) were incubated with serial dilutions of each recombinant protein for 72 h at 37°C and 5% CO₂ in a 96-well plate. We also set up controls of untreated cells (100% proliferation) and cells treated with zeocin (0% proliferation). We added 50 μl XTT/phenazine methosulfate and incubated the cells for 4 h at 37°C and 5% CO₂ before measuring the absorbance at 450 nm and the reference wavelength at 630 nm in an Epoch Microplate Spectrophotometer. The half maximal inhibitory concentration (EC_{50}) of each protein was estimated using the three-parameter dose-response curve fit equation and the significance of the dose-response effect was estimated by two-way analysis of variance (ANOVA) with Bonferroni’s post hoc test using GraphPad Prism v5 software (GraphPad Software Inc., San Diego, California).

Annexin V/propidium iodide (PI) staining was used to determine the pro-apoptotic effect of the recombinant proteins TTC-ETA', GrB(R201K)-TTC and TTC-MAPTau. TTC-reactive REH cells and control cells (1x10^5 cell per sample) were incubated with 50 nM of each recombinant protein or with camptothecin as a positive control in a 24-well plate for 72 h at 37°C and 5% CO₂. The cells and the supernatant were then transferred to a FACS tube and washed with 500 μl annexin buffer (10 nM HEPES, 140 mM NaCl, 25 mM CaCl₂, pH 7.4). The cells were then pelleted (500 x g, 5 min, 4°C) and incubated with annexin V allophycocyanin (APC) conjugate diluted 1:50 (eBioscience, San Diego, California) for 20 min in the dark. After a final washing step with annexin buffer, the cells were re-suspended in annexin buffer and stained with 1 μg/ml PI before analysis in a FACSVerse instrument. The different states of the cells (viable, early apoptotic and late apoptotic/necrotic) were determined and analyzed by one-way ANOVA followed by the Bonferroni’s post hoc test using GraphPad Prism v5.

**Results**

**Generation of a TTC-reactive lymphocytic REH cell line using the piggyBac transposon system**

Human lymphocytic REH cells presenting TTC-reactive antibodies were prepared by isolating the DNA sequences encoding the TTC-specific antibody produced by the murine hybridoma cell line 5E4. The murine hybridoma cells were harvested, RNA was isolated and reverse transcribed into cDNA. The specific V_H and V_L fragments were amplified by PCR and integrated into expression vectors containing the transposon sequences (Fig 1A). The transposase system requires co-transfection with a plasmid providing the transposase. The lymphocytic REH cells were therefore simultaneously co-transfected with the V_H/V_L transposon plasmids (Fig 1A) and pcDNA3.1-hy-mPB containing the piggyBac transposase gene (Fig 1B).

FACS analysis for the reporter protein eGFP indicated a transfection efficiency of ~7% for both transfection steps (TTC-reactive, mock-reactive plasmids) compared to untransfected REH cells (Fig 2A). Positive TTC-reactive REH cells carrying the specific antibody on the cell surface were analyzed using the SNAP-TTC-BG-647 protein. FACS analysis revealed the specific binding of SNAP-TTC-BG-647 to the TTC-reactive cell population (2% of the REH cells presented the TTC-reactive BCR on the cell surface). The population of transfected REH cells that achieved strong binding to the SNAP-TTC-BG-647 protein, indicated by a positive fluorescence signal in the APC channel, was sorted and cultivated (Fig 2B). The TTC-reactive REH cell population was 85% enriched for BCR-positive cells after the first sorting round (Fig 2B, middle) and this increased to more than 92% after the second round (Fig 2B, right). A negative control cell line was generated in the same way using the pPB-LC/HC-AC10-EGFP expression vectors [39], encoding the CD30-specific monoclonal antibody AC10 (mock-transfected REH cells) (Fig 2A). These control cells were also sorted and cultivated as above and were used as negative controls in subsequent experiments.
Internalization of the fusion proteins by the TTC-reactive lymphocytic REH cell population

Internalization assays were carried out to characterize the functionality of the novel fusion proteins in the presence of human TTC-reactive REH cells. When the cells were incubated at 4˚C, specific binding of the SNAP-TTC-BG-647 protein was observed (Fig 3A). Efficient TTC-specific internalization of the protein was demonstrated using SNAP-TTC-BG-647, revealing the intracellular accumulation of the red-labeled protein after incubation at 37˚C for 30 min (Fig 3B) compared to the untreated TTC-reactive REH cells (Fig 3C). The control mock-transfected REH cells showed no evidence of nonspecific protein binding and internalization (Fig 3D).

Generation and characterization of the GrB(R201K)-TTC cytolytic fusion protein

The TTC DNA sequence was transferred to pMS expression vectors containing the coding sequences for cytotoxic domains GrB(R201K) and MAPTau (Fig 4A) and the recombinant vectors were verified by DNA sequencing. HEK 293T cells were transfected with each of the vectors and the recombinant fusion proteins EGrB(R21K)-TTC and TTC-MAPTau were purified from the cell supernatant by IMAC with yields of 4.5 mg/l EGrB(R21K)-TTC and 1.6
mg/l TTC-MAPtau (Fig 4B). EgBr(R201K)-TTC was activated by in vitro enterokinase digestion to expose the N-terminal enterokinase site and the proteolytic activity of GrB-(R201K)-TTC and the corresponding control construct GrB(R201K)-Mock was confirmed using the synthetic substrate Ac-IETD-pNA. The non-cleaved EgBr(R201K)-TTC protein showed no activity as expected (Fig 4C). An XTT-based cell viability assay using the mouse TTC-reactive hybridoma cell line 5E4 confirmed that the GrB(R201K)-TTC and TTC-MAPtau proteins showed no cross-reactivity with the murine cells and therefore no cytotoxicity. In contrast, the TTC-ETA' immunotoxin showed dose-dependent cytotoxicity towards these murine cells [26].

The TTC-reactive REH cells were then used as a test system in order to characterize the novel TTC-based fusion proteins GrB(R201K)-TTC and TTC-MAPtau. Specific binding of the TTC-based fusion proteins to the TTC-reactive REH cells was compared to the mock-transfected REH control cells by FACS (Fig 5). Parallel experiments using mock-proteins with the corresponding effector domains confirmed that the specific binding was not affected by the effector domain of the fusion proteins. The mock-proteins, which have the same effector domain but a different cell-binding domain, showed no evidence of nonspecific binding to the transfected REH cells (Fig 5).

**Specific cytotoxicity and pro-apoptotic activity**

The XTT cell viability assay revealed that both the TTC-ETA' protein and the cytolytic GrB (R201K)-TTC protein showed dose-dependent toxicity towards REH cells after incubation for 72 h. As summarized in Table 2, the EC50 values were 0.76 ± 0.13 nM (x ± SD, n = 3) for
TTC-ETA’ and 5.0 ± 1.5 nM (x ± SD, n = 3) for GrB(R201K)-TTC, compared to untreated cells (100% cell viability) and the positive control zeocin (0% viability). A statistically significant reduction in cell viability was observed for both TTC-ETA’ (p < 0.001, Fig 6A) and GrB(R201K)-TTC (p < 0.001, Fig 6B) compared to the mock-reactive REH control cells, analyzed by two-way ANOVA followed by Bonferroni’s post-hoc test. For TTC-MAPTau, concentrations above 18 nM showed a specific killing effect on the TTC-reactive REH cells, only at the highest applied concentration, the construct had a marginal impact on cell viability on mock-transfected REH cells (Fig 6C). The control TTC protein (without an effector domain) did not affect the viability of the TTC-reactive REH or control cells (S1 Fig).

The ability of the TTC fusion proteins to induce apoptosis was measured by annexin V/PI staining. Briefly, the cells were incubated for 72 h at 37˚C using 50 nM TTC, TTC-ETA’, GrB(R201K)-TTC or TTC-MAPTau, or the corresponding mock-control proteins (Mock-ETA’, GrB(R201K)-Mock, or Mock-MAPTau). Fig 7A shows representative dot blots for each protein tested against TTC-reactive-REH or control REH cells. The proportion of the TTC-reactive REH cell population induced to undergo apoptosis was ~72% for TTC-ETA’ and ~45.5% for GrB(R201K)-TTC but only 20% for TTC-MAPTau (Fig 7B, left diagram). As expected,
none of the proteins had a significant impact on the proportion of apoptotic cells in the control cell line (Fig 7B, right diagram).

**Discussion**

Current strategies for the treatment of autoimmune diseases using monoclonal antibodies that target B cells show systemic effects. The targeting of CD19, CD20 or CD22 eliminates entire B cell subpopulations resulting in severe side effects such as a higher risk of concomitant infections [17, 19]. In contrast, our strategy targets the unique BCRs found on B cells. Antigen-based fusion proteins using ETA’ or diphtheria toxin A (DTA) as cytotoxic domains have shown promising therapeutic effects against autoimmune diseases. For example, multiple sclerosis has been treated by targeting the autoantigen myelin oligodendrocyte glycoprotein (MOG) with immunotoxins containing ETA’ or DTA, resulting in the specific depletion of the autoreactive cell population in mouse models [57, 58]. In our additional proof of concept study [26], we confirmed the specific targeting and depletion of human memory B cells using an antigen-specific fusion protein containing ETA’.

Immunotoxins containing bacterial or plant toxins can potentially trigger an immune response in humans, which limits the therapeutic application to one or two doses before the patient eventually develops neutralizing antibodies against effector domain or the cell-binding

### Table 2. EC\textsubscript{50} values of TTC-fusion proteins on TTC-reactive REH cells.

| Fusion Protein          | EC\textsubscript{50} (\(x \pm SD\)) |
|-------------------------|------------------------------------|
| TTC-ETA’                | 0.76 ± 0.13 nM                     |
| GrB(R201K)-TTC          | 5.0 ± 1.5 nM                       |
| TTC-MAPTau              | not detectable                     |

After the XTT cell viability assay, see Fig 6, the EC\textsubscript{50} values of the different TTC-fusion proteins were calculated. They indicated the required protein concentration to achieve a 50% reduction of the cell viability.

https://doi.org/10.1371/journal.pone.0180305.t002
domain [29, 59]. To overcome this challenge, a new generation of immunotoxins has been developed containing human pro-apoptotic proteins such as granzyme B, angiogenin or MAP-Tau [21, 27–30, 54, 60, 61]. We therefore used the established pMS vector system [53] to prepare fusion constructs combining two human effector proteins with TTC as a model antigen, resulting in two novel TTC-based fusion proteins: EGrB(R201K)-TTC and TTC-MAPTau.

These proteins were expressed successfully following the transfection of HEK 293T cells, and the expression yield of the protein EGrB(R201K)-TTC we achieved (4.5 mg/l) is comparable to the yields of other granzyme B fusion proteins produced in HEK 293T cells, ranging from 1 to 30 mg/l [30, 32, 62]. The yield of TTC-MAPTau was 1.6 mg/l, which is comparable to other MAPtau fusion proteins such as Ki4scFv-MAP and anti-EpCAMscFv-MAP produced in E. coli with yields of up to 1 mg/l [60, 63, 64]. Eukaryotic expression systems offer the advantage of endotoxin-free fusion protein production, so that additional purification steps are unnecessary. We confirmed the enzymatic activity of the granzyme B fusion protein using an appropriate substrate assay (Fig 4C). However, neither EGrB(R201K)-TTC nor TTC-MAPTau were cytotoxic towards the murine TTC-reactive hybridoma cell line 5E4, due to their species-dependent activity (Fig 4D). A novel TTC-reactive human lymphocytic cell line was therefore necessary for the in vitro characterization of the cytolytic fusion proteins.

Stable mammalian cell lines presenting or expressing specific recombinant proteins can be produced using diverse techniques such as retroviral/lentiviral vectors [65], transient transfection with plasmid DNA [66] or transposon-based gene transfer systems [44–47, 67]. Several reports have demonstrated the generation of tailor-made human lymphocytic cell lines using transposon-based gene transfer [39, 44, 47, 68–70]. We used Transpo-mAb™ technology to establish a human cell line displaying a TTC-reactive BCR on the cell surface. We found that it was possible to transfect mammalian lymphocytic REH cells (precursor B cells) and achieve
Fig 7. Annexin V/PI-staining of TTC-reactive REH cells and control cells treated with TTC fusion proteins and equivalent control proteins. The assay was carried out after incubating the TTC-reactive REH cells (A) or control REH
the same transfection efficiency usually reported for electroporation [39]. This allowed us to express a full-length antibody sequence that underwent all the correct folding and post-translational modifications required for the presentation of a functional antibody on a human B cell line. Transposon-based gene transfer provides a rapid and straightforward method to generate a human artificial cellular test system featuring any antibody of interest requiring only 2–3 months of laboratory work. The generation of a B cell line presenting a human antibody would be much more expensive and laborious using hybridoma technology [71].

The REH cells maintained their lymphocytic behavior after transfection, as shown by the rapid receptor-mediated internalization of the SNAP-TTC-BG-647 protein bound to the TTC-reactive BCR (Fig 3). The efficiency of internalization was comparable to the rate of BCR endocytosis observed in isolated lymphocytic cells [72–74]. The novel TTC-reactive REH cell line continued to present the specific anti-TTC antibody on the cell surface for a cultivation period of 1–2 months, which is comparable to previous reports [39]. The novel human TTC-reactive lymphocytic REH cell population can thus serve as valuable in vitro test system for the characterization of novel cytolytic fusion proteins such as GrB(R201K)-TTC and TTC-MAP-Tau. Transpo-mAb™ technology therefore appears to be ideal for the high-throughput analysis of novel therapeutic antibodies and fusion proteins, and also for epitope mapping analysis, not only in the field of autoimmune disorders (characterized by a low frequency of autoreactive memory B cells) but also for the characterization of specific memory B cells in the field of infectious diseases such as malaria, Ebola and dengue fever.

We used the new artificial cellular test system for the in vitro characterization of the TTC-based fusion proteins starting with their cell-binding properties. As expected, all TTC-based proteins bound specifically to the BCR of the TTC-reactive REH cells but not to the mock-transfected control REH cells (Fig 5). A small amount of granzyme B binds nonspecifically to the REH cells due to the high isoelectric point of the protein and the positive surface charge of the cells, as indicated by a small shift in fluorescence signal [75–77]. However, the GrB(R201K)-TTC fusion protein predominantly bound specifically to the TTC-reactive REH cells.

The TTC-ETA’ protein was used as a positive control to show the specific binding and depletion of the human TTC-reactive REH cells (Figs 5 and 6A) with a low EC_{50} value in the picomolar range. In contrast, the EC_{50} value of GrB(R201K)-TTC against REH cells was 5 nM (Fig 6B), which is in the same range or slightly lower than other granzyme B fusion proteins targeting cancer cells such as GbR201K-Ki4(scFv) against L540cy cells (EC_{50} = 1.7 nM), GbR201K-scFv1711 against RD cells (EC_{50} = 21.1 nM), or the anti-malarial activity of granzyme B (EC_{50} = 176 nM) [30, 32, 54, 56, 78].

The TTC-MAPTau protein was much less potent than GrB(R201K)-TTC and reduced cell proliferation by only 20% (Fig 6C). This may reflect the low proliferation rate of the transfected REH cells: under these circumstances, the interruption of dynamic microtubule assembly and disassembly by MAPTau might not induce apoptosis within the time frame of the experiment. Cells with high proliferation rates, such as cancer cells, are more sensitive to MAPTau, as demonstrated in earlier studies testing MAPTau fusion proteins as candidates for cancer therapy.
For example, EGF-MAP achieved a half-maximal inhibitory concentration (IC\textsubscript{50}) of 1 μM against pancreatic L3.6pl cells, and Ki(scFv)-MAP achieved an IC\textsubscript{50} value of 53 nM against the Hodgkin’s lymphoma cell line L540cy [60, 63, 64]. Autoreactive memory B cells are also characterized by slow proliferation, so MAPTau fusion proteins may be less useful than granzyme B fusion proteins in this context. However, if the memory B cells contact the autoantigen and differentiate into rapidly-proliferating plasma blasts [79], the MAPTau protein effector domain could have a more potent effect on the dynamic behavior of microtubules resulting in the rapid induction of apoptosis.

GrB(R201K)-TTC induced apoptosis much more efficiently than TTC-MAPTau in human lymphocytic REH cells (Fig 7). We have therefore demonstrated that human artificial antigen-specific B lymphocytes can be targeted and eliminated using a TTC-based fusion protein with GrB(R201K) as the effector domain. This suggests that such antigen-based fusion proteins could also be suitable for the antigen-specific elimination of autoreactive human B cells \textit{in vivo} to as a novel strategy for the treatment of autoimmune disorders.

**Conclusion**

Transpo-mAb\textsuperscript{TM} technology facilitates the simple and rapid generation of antigen-specific BCRs on the surface of mammalian cells using \textit{piggyBac} transposase. We expressed a chimeric TTC-specific antibody on the surface of human lymphocytic REH cells, in which the constant regions were human in origin and only the variable regions (V\textsubscript{L}/V\textsubscript{H}) were derived from the murine antibody. The human lymphocytic REH cells provide a valuable \textit{in vitro} test system to characterize antigen-specific human cytolytic fusion proteins. This technology has the potential to facilitate high-throughput screening for novel antibodies, antibody–drug conjugates and cytolytic fusion proteins applicable to a wide range of diseases, including cancer, infections and autoimmune diseases.

Our antigen-specific fusion protein containing the granzyme B (R201K) mutant as the toxic component efficiently eliminated human B cells as demonstrated by annexin V/PI staining and XTT-based cell proliferation assays. These results confirm that the granzyme B (R201K) mutant is a promising effector domain for the treatment of B cell-driven autoimmune diseases such as SLE, lupus nephritis and multiple sclerosis. The potential of the GrB(R201K)-TTC fusion protein for the elimination of autoreactive human B cells must now be tested \textit{in vivo}.

**Supporting information**

**S1 Fig. XTT cell viability assay to determine the cytotoxicity of TTC protein.** TTC-reactive REH cells (black) as well as the mock-transfected control REH cells (gray) were used to demonstrate the cytotoxicity of TTC protein without a fused effector domain (♣). The cells were incubated with an increasing concentration of the recombinant fusion proteins for 72 h at 37°C and 5% CO\textsubscript{2} followed by an XTT cell viability assay. As no cytotoxicity could be measured using the applied concentrations, no EC\textsubscript{50} value could be determined.

(TIF)

**S1 Table. Raw data of the granzyme B substrate assay.**

(XLSX)

**S2 Table. Raw data of the XTT assay.**

(XLSX)

**S3 Table. Raw data of the annexin V assay.**

(XLSX)
Acknowledgments

The authors would like to thank Christoph Stein, Severin Schnies (Fraunhofer IME) and Grit Hehmann-Titt (Pharmedartis GmbH) for providing the control mock-proteins, and Dr. Richard M Twyman for critically reading the manuscript.

Author Contributions

Conceptualization: DK SB R. Fendel TN.
Formal analysis: DK R. Fendel.
Funding acquisition: DK R. Fischer SB TN.
Investigation: DK MW JN R. Fendel.
Methodology: DK R. Fendel TN.
Project administration: DK SB TN.
Resources: RRB UG.
Supervision: R. Fischer SB R. Fendel TN.
Writing – original draft: DK R. Fendel TN.
Writing – review & editing: DK MW JN R. Fendel TN.

References

1. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood. 2008; 112(5):1570–80. https://doi.org/10.1182/blood-2008-02-078071 PMID: 18725575
2. Townsend MJ, Monroe JG, Chan AC. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev. 2010; 237:264–83. https://doi.org/10.1111/j.1600-065X.2010.00945.x PMID: 20727041
3. Davidson A, Diamond B. Autoimmune diseases. The New England journal of medicine. 2001; 345(5):340–50. Epub 2001/08/04. https://doi.org/10.1056/NEJM20010823450506 PMID: 11484692.
4. Dorner T, Jacobi AM, Lipsky PE. B cells in autoimmunity. Arthritis Res Ther. 2009; 11(5). https://doi.org/10.1186/ar2780 PMID: 19849820
5. Engel P, Gomez-Puerta JA, Ramos-Casals M, Lozano F, Bosch X. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacological reviews. 2011; 63(1):127–56. Epub 2011/01/20. https://doi.org/10.1124/pr.109.002006 PMID: 21245206.
6. Shlomchik MJ, Craft JE, Mamula MJ. From T to B and back again: positive feedback in systemic autoimmune disease. Nature reviews Immunology. 2001; 1(2):147–53. Epub 2002/03/22. https://doi.org/10.1038/35100573 PMID: 11905822.
7. Yurasov S, Wardemann H, Hammersen J, Tsuiji M, Meffre E, Pascual V, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005; 201(5):703–11. https://doi.org/10.1084/jem.20042251 PMID: 15738055
8. Dorner T, Jacobi AM, Lee J, Lipsky PE. Abnormalities of B cell subsets in patients with systemic lupus erythematosus. Journal of immunological methods. 2011; 363(2):187–97. Epub 2010/07/06. https://doi.org/10.1016/j.jim.2010.06.009 PMID: 20598709.
9. Hampe CS. B cells in Autoimmune Diseases. Scientifica. 2012; 2012:18. https://doi.org/10.6064/2012/215308 PMID: 23807906
10. Hostmann A, Jacobi AM, Mei H, Hiepe F, Dorner T. Peripheral B cell abnormalities and disease activity in systemic lupus erythematosus. Lupus. 2008; 17(12):1064–9. https://doi.org/10.1177/0961233908095138 PMID: 19029273
11. Kamen DL, Zollars ES. Corticosteroids in Lupus Nephritis and Central Nervous System Lupus. Rheum Dis Clin N Am. 2016; 42(1):63+. https://doi.org/10.1016/j.rdc.2015.08.008 PMID: 26611551
12. Lee SJ, Silverman E, Bargman JM. The role of antimalarial agents in the treatment of SLE and lupus nephritis. Nat Rev Nephrol. 2011; 7(12):718–29. https://doi.org/10.1038/nrneph.2011.150 PMID: 22009248

13. Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immun. 2011; 127(2):303–12. https://doi.org/10.1016/j.jaci.2010.12.1087 PMID: 21281862

14. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nature reviews Immunology. 2010; 10(5):301–14. Epub 2010/04/24. https://doi.org/10.1038/nri2761 PMID: 20414204.

15. Jacob N, Stohl W. Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity. 2010; 43(1):84–97. Epub 2009/12/18. https://doi.org/10.3109/08916930903374600 PMID: 20014977; PubMed Central PMCID: PMC2809122.

16. Ahijon Lana M, Fattah Z, Fernandez SA, Isenberg DA. Systemic Lupus Erythematosus: Direct B-Cell Blocking. In: Parnham M, Bruinvels J., editor. Drugs Targeting B-Cells in Autoimmune Diseases Series: Milestones in Drug Therapy. Springer Basel; 2014. p. 65–78.

17. Hoyer BF, Dorner T. Biologics therapy for systemic lupus erythematosus. Current situation. Z Rheumatol. 2015; 74(3):206–14. https://doi.org/10.1007/s00393-014-1458-0 PMID: 25854155.

18. Sciascia S, Talavera-Garcia E, Roccatello D, Baldovino S, Mengatti E, Cuadrado MJ. Upcoming biological therapies in systemic lupus erythematosus. Int Immunopharmacol. 2015; 27(2):189–93. https://doi.org/10.1016/j.intimp.2015.04.049 PMID: 26028152

19. Dorner T, Shock A, Goldenberg DM, Lipsky PE. The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. Autoimm Rev. 2015; 14(12):1079–86. https://doi.org/10.1016/j.autrev.2015.07.013 PMID: 26212727

20. Mirabelli G, Cannarile F, Bruni C, Vagelli R, De Luca R, Carli L. One year in review 2015: systemic lupus erythematosus. Clin Exp Rheumatol. 2015; 33(3):414–25. PMID: 26106941

21. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nature reviews Cancer. 2006; 6(7):559–65. Epub 2006/06/24. https://doi.org/10.1038/nrc1891 PMID: 16794638.

22. Wayne AS, Fitzgerald DJ, Kreitman RJ, Pastan I. Immunotoxins for leukemia. Blood. 2014; 123(16):2470–7. https://doi.org/10.1182/blood-2014-01-492256 PMID: 24578503; PubMed Central PMCID: PMC3990911.

23. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15(16):5274–9. https://doi.org/10.1158/1078-0432.CCR-09-0062 PMID: 19671873; PubMed Central PMCID: PMC2754261.

24. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, Wilson WH, et al. Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2009; 27(18):2983–90. https://doi.org/10.1200/JCO.2008.20.2630 PMID: 19144673; PubMed Central PMCID: PMC2702232.

25. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumumab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30(15):1822–8. https://doi.org/10.1200/JCO.2011.38.1756 PMID: 22355053; PubMed Central PMCID: PMC3383181.

26. Kloose D, Saunders U, Barth S, Fischer R, Jacobi AM, Nachreiner T. Novel fusion proteins for the antigen-specific staining and elimination of B cell receptor-positive cell populations demonstrated by a tetanus toxoid fragment C (TTC) model antigen. Bmc Biotechnol. 2016; 16. https://doi.org/10.1186/s12896-016-0249-x PMID: 26883813

27. Cremer C, Vierbuchen T, Hein L, Fischer R, Barth S, Nachreiner T. Angiogenin mutants as novel effector molecules for the generation of fusion proteins with increased cytotoxic potential. Journal of immunotherapy. 2015; 38(3):85–95. https://doi.org/10.1097/CJI.0000000000000553 PMID: 25710248.

28. Losasso V, Schiffer S, Barth S, Carlson P. Design of human granzyme B variants resistant to serpin B9. Proteins. 2012; 80(11):2514–22. Epub 2012/06/27. https://doi.org/10.1002/prot.24133 PMID: 22733450.

29. Mathew M, Verma RS. Humanized immunotoxins: a new generation of immunotoxins for targeted cancer therapy. Cancer science. 2009; 100(8):1355–65. https://doi.org/10.1111/j.1349-7006.2009.01192.x PMID: 19459847.

30. Schiffer S, Hansen HP, Hehmann-Titt G, Huhn M, Fischer R, Barth S, et al. Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-8-positive classical Hodgkin lymphoma cells in a murine model. Blood cancer journal. 2013; 3:e106. https://doi.org/10.1038/bcj.2013.4 PMID: 23524591; PubMed Central PMCID: PMC3615217.
31. Weldon JE, Pastan I. A guide to taming a toxin—recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. The FEBS journal. 2011; 278(23):4683–700. https://doi.org/10.1111/j.1742-4658.2011.08182.x PMID: 21585657; PubMed Central PMCID: PMC3179548.

32. Niesen J, Stein C, Brehm H, Hehrmann-Titt G, Fendel R, Melmer G, et al. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities. J Cancer Res Clin. 2015; 141(12):2079–95. https://doi.org/10.1007/s00432-015-1975-5 PMID: 25899161

33. Trinczek B, Biernat J, Baumann K, Mandelkow EM, Mandelkow E. Domains of Tau-Protein, Differential Phosphorylation, and Dynamic Instability of Microtubules. Mol Biol Cell. 1995; 6(12):1887–902. PMID: 8590813

34. Mandelkow E, Mandelkow EM. Microtubules and Microtubule-Associated Proteins. Curr Opin Cell Biol. 1995; 7(1):72–81. https://doi.org/10.1016/0955-0674(95)80047-6 PMID: 7755992

35. Waldmeier L, Hellmann I, Gutknecht CK, Wolter FI, Cook SC, Reddy ST, et al. Transpo-mAb display: Transposition-mediated B cell display and functional screening of full-length IgG antibody libraries. MAbs. 2016; 8(4):726–40. https://doi.org/10.1080/19420862.2016.1160990 PMID: 26986818; PubMed Central PMCID: PMC4668644.

36. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu Rev Med. 2007; 58:221–37. https://doi.org/10.1146/annurev.med.58.070605.115320 PMID: 17059365

37. Grawunder U, inventor; NBE-Therapeutics LLC, assignee. Transposition-mediated identification of specific binding or functional proteins. CH2014.

38. Munoz-Lopez M, Garcia-Perez JL. DNA Transposons: Nature and Applications in Genomics. Curr Genomics. 2010; 11(2):115–28. https://doi.org/10.2174/138920210790886871 PMID: 20885819

39. Hristodorov D, Mladenov R, Pardo A, Pham AT, Huhn M, Fischer R, et al. Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo. Brit J Cancer. 2013; 109(6):1570–8. https://doi.org/10.1038/bjc.2013.457 PMID: 23942071

40. Skipper KA, Andersen PR, Sharma N, Mikkelsen JG. DNA transposon-based gene vehicles—scenarios from an evolutionary drive. J Biomed Sci. 2013; 20. https://doi.org/10.1186/1423-0127-20-92 PMID: 23420156

41. Antoniou MN, Skipper KA, Anakok O. Optimizing Retroviral Gene Expression for Effective Therapies. Hum Gene Ther. 2013; 24(4):363–74. https://doi.org/10.1089/hum.2013.062 PMID: 23517535

42. Saha S, Woodard LE, Charron EM, Welch RC, Rooney CM, Wilson MH. Evaluating the potential for undesired genomic effects of the piggyBac transposon system in human cells. Nucleic Acids Res. 2015; 43(3):1770–82. https://doi.org/10.1093/nar/gkv017 PMID: 25605795

43. Di Matteo M, Samara-Kuko E, Ward NJ, Waddington SN, McVey JH, Chuah MK, et al. Hyperactive piggyBac transposons for sustained and robust liver-targeted gene therapy. Molecular therapy: the journal of the American Society of Gene Therapy. 2014; 22(9):1614–24. https://doi.org/10.1038/mtn.2014.131 PMID: 25034357.

44. Multani SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, et al. Sleeping beauty system to redirect T-cell specificity for human applications. Journal of immunotherapy. 2013; 36(2):112–23. https://doi.org/10.1097/JIT.0b013e3182e118c9 PMID: 23377665; PubMed Central PMCID: PMC3568214.

45. Nakazawa Y, Huye LE, Dotti G, Foster AE, Vera JF, Manuri PR, et al. Optimization of the PiggyBac Transposon System for the Sustained Genetic Modification of Human T Lymphocytes. Journal of immunotherapy. 2009; 32(8):826–36. https://doi.org/10.1097/CJI.0b013e3181ad762b PMID: 19752751

46. Saha S, Nakazawa Y, Huye LE, Doherty JE, Galvan DL, Rooney CM, et al. piggyBac transposon system modification of primary human T cells. Journal of visualized experiments: JoVE. 2012;(69):e4235. https://doi.org/10.3791/4235 PMID: 23149543; PubMed Central PMCID: PMC3514050.

47. Yusa K, Zhou L, Li MA, Bradley A, Craig NL. A hyperactive piggyBac transposase for mammalian applications. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(4):1531–6. https://doi.org/10.1073/pnas.1008322108 PMID: 21205896; PubMed Central PMCID: PMC3029773.

48. Fitzsimmons SP, Clark KC, Wilkerson R, Shapiro MA. Inhibition of tetanus toxin fragment C binding to ganglioside G(T1b) by monoclonal antibodies recognizing different epitopes. Vaccine. 2000; 19(1):114–21. Epub 2000/08/05. PMID: 10924793.

49. Rosenfeld C, Goutner A, Choquet C, Venuat AM, Kayibanda B, Pico JL, et al. Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line. Nature. 1977; 267(5614):841–3. PMID: 197411.

50. Bialon M, Schellenberg L, Herzog N, Kraus S, Jorissen H, Fischer R, et al. Cloning murine antibody V genes with non-degenerate primers and conversion to a recombinant antibody format. Monoclonal
antibodies in immunodiagnosis and immunotherapy. 2014; 33(6):369–77. https://doi.org/10.1089/mab.2014.0044 PMID: 25545205; PubMed Central PMCID: PMC4278175.

51. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 2002; 30(2). https://doi.org/10.1093/nar/30.2.e9

52. Kapeliski S, Boes A, Spiegel H, de Almeida M, Klockenbring T, Reimann A, et al. Fast track antibody V-gene rescue, recombinant expression in plants and characterization of a PmMP4-specific antibody. Malaria J. 2015; 14. https://doi.org/10.1186/s12936-015-0577-7 PMID: 25651860

53. Stocker M, Tur MK, Sasse S, Krussmann A, Barth S, Engert A. Secretion of functional anti-CD30-angio-genin immunotoxins into the supernatant of transfected 293T-cells. Protein expression and purification. 2003; 28(2):211–9. Epub 2003/04/18. PMID: 12699683.

54. Schiller S, Rosinke R, Jost E, Hehmann-Titt G, Huhn M, Melmer G, et al. Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins. Int J Cancer. 2014; 135(6):1497–508. https://doi.org/10.1002/ijc.28786 PMID: 24523193

55. Kampmeier F, Ribbert M, Nachreiner T, Dembski S, Beautulis F, Brecht A, et al. Site-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferase. Bioconjug Chem. 2009; 20(5):1010–5. Epub 2009/04/25. https://doi.org/10.1021/bc800257 PMID: 19386673.

56. Stahnke B, Thepen T, Stocker M, Rosinke R, Jost E, Fischer R, et al. Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Mol Cancer Ther. 2008; 7(9):2924–32. https://doi.org/10.1158/1535-7163.MCT-08-0554 PMID: 18790773

57. Nachreiner T, Kampmeier F, Thepen T, Fischer R, Barth S, Stocker M. Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin. Journal of neuroimmunology. 2008; 195(1–2):28–35. Epub 2008/02/19. https://doi.org/10.1016/j.jneuroim.2008.01.001 PMID: 18280586.

58. Stepanov A, Belya A, Kasheverov I, Rybinets A, Dronina M, Dyachenko I, et al. Development of a therapeutic enzymes: considerations for testing, prevention and treatment. Nature biotechnology. 2008; 26(9):901–8. https://doi.org/10.1038/nbt.1484 PMID: 18688246; PubMed Central PMCID: PMC3478093.

59. Wang J, Lozier J, Johnson G, Kirshner S, Vertherly D, Pariser A, et al. Neutralizing antibodies to therapeuetic enzymes: considerations for testing, prevention and treatment. Nature biotechnology. 2008; 26(8):901–8. https://doi.org/10.1038/nbt.1484 PMID: 18688246; PubMed Central PMCID: PMC3478093.

60. Hristodorov D, Amoury M, Mladenov R, Niesen J, Arens K, Berges N, et al. EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein. Mol Cancer Ther. 2014; 13(9):2194–202. https://doi.org/10.1158/1535-7163.MCT-13-0781 PMID: 24980949.

61. Schiller S, Letzian S, Jost E, Mladenov R, Hristodorov D, Huhn M, et al. Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells. Cancer letters. 2013; 341(2):176–65. https://doi.org/10.1016/j.canlet.2013.08.005 PMID: 23973499.

62. Niesen J, Brehm H, Stein C, Berges N, Pardo A, Fischer R, et al. In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells. J Cancer Res Clin. 2015; 141(6):1049–61. https://doi.org/10.1007/s10026-014-1884-z PMID: 25433506

63. Brehm H, Hristodorov D, Pardo A, Mladenov R, Niesen J, Fischer R, et al. Targeted killing of rhabdo-myosarcoma cells by a MAP-based human cytolytic fusion protein. Cancer letters. 2015; 365(2):149–55. https://doi.org/10.1016/j.canlet.2015.04.004 PMID: 25888452

64. Hristodorov D, Nordhojne J, Mladenov R, Huhn M, Fischer R, Thepen T, et al. Human microtubule-associated protein tau mediates targeted killing of CD30(+) lymphoma cells in vitro and inhibits tumour growth in vivo. British journal of haematology. 2014; 164(2):251–7. https://doi.org/10.1111/bjh.12629 PMID: 24164493.

65. Walther W, Stein U. Viral vectors for gene transfer: a review of their use in the treatment of human diseases. Drugs. 2000; 60(2):249–71. PMID: 10983732.

66. Horlick RA, Macomber JL, Bowers PM, Neben TY, Tomlinson GL, Krapf IP, et al. Simultaneous Surface Display and Secretion of Proteins from Mammalian Cells Facilitate Efficient in Vivo Selection and Maturation of Antibodies. J Biol Chem. 2013; 288(27):19861–9. https://doi.org/10.1074/jbc.M113.452482 PMID: 23689374

67. Wilber A, Linehan JL, Tian X, Woll PS, Morris JK, Belur LR, et al. Efficient and stable transgene expression in human embryonic stem cells using transposon-mediated gene transfer. Stem cells. 2007; 25(11):2919–27. https://doi.org/10.1634/stemcells.2007-0026 PMID: 17673526.
68. Doherty JE, Huye LE, Yusa K, Zhou L, Craig NL, Wilson MH. Hyperactive piggyBac gene transfer in human cells and in vivo. Hum Gene Ther. 2012; 23(3):311–20. https://doi.org/10.1089/hum.2011.138 PMID: 21992617; PubMed Central PMCID: PMC3300075.

69. Rad R, Rad L, Wang W, Cadinanos J, Vassiliou G, Rice S, et al. PiggyBac Transposon Mutagenesis: A Tool for Cancer Gene Discovery in Mice. Science. 2010; 330(6007):1104–7. https://doi.org/10.1126/science.1193004 PMID: 20947725.

70. Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, et al. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PloS one. 2013; 8(5):e64138. https://doi.org/10.1371/journal.pone.0064138 PMID: 23741305; PubMed Central PMCID: PMC3669363.

71. Goding JW. Antibody-Production by Hybridomas. Journal of immunological methods. 1980; 39:285–308. https://doi.org/10.1016/0022-1759(80)90230-6 PMID: 7007515.

72. Malhotra S, Kovats S, Zhang WG, Coggleshall KM. B Cell Antigen Receptor Endocytosis and Antigen Presentation to T Cells Require Vav and Dynamin. J Biol Chem. 2009; 284(36):24088–97. https://doi.org/10.1074/jbc.M109.014209 PMID: 19586920.

73. Stoddart A, Jackson AP, Brodsky FM. Plasticity of B cell receptor internalization upon conditional depletion of clathrin. Mol Biol Cell. 2005; 16(5):2339–48. https://doi.org/10.1091/mbc.E05-01-0025 PMID: 15716350.

74. Chaturvedi A, Martz R, Dorward D, Waisberg M, Pierce SK. Endocytosed BCRs sequentially regulate MAPK and Akt signaling pathways from intracellular compartments. Nat Immunol. 2011; 12(11):1119–U130. https://doi.org/10.1038/ni.2116 PMID: 21964606.

75. Hehmann-Titt G, Schiffer S, Berges N, Melmer G, Barth S. Improving the Therapeutic Potential of Human Granzyme B for Targeted Cancer Therapy. Antibodies. 2013; 2(1):19. https://doi.org/10.3390/antib2010019.

76. Jabulowsky RA, Oberoi P, Bahr-Mahmud H, Wels WS. Surface Charge-Modification Prevents Sequestration and Enhances Tumor-Cell Specificity of a Recombinant Granzyme B-TGF alpha Fusion Protein. Bioconjugate Chem. 2012; 23(8):1567–76. https://doi.org/10.1021/bc3000657 PMID: 22759275.

77. Weidle UH, Georges G, Brinkmann U. Fully Human Targeted Cytotoxic Fusion Proteins: New Anticancer Agents on the Horizon. Cancer Genom Proteom. 2012; 9(3):119–33.

78. Kapelski S, de Almeida M, Fischer R, Barth S, Fendel R. Antimalarial activity of granzyme B and its targeted delivery by a granzyme B-single-chain Fv fusion protein. Antimicrob Agents Chemother. 2015; 59(1):669–72. https://doi.org/10.1128/AAC.04190-14 PMID: 25313223; PubMed Central PMCID: PMC4291407.

79. Tarlinton DM, Smith KGC. How many memories does it take to make an SLE flare? Nat Immunol. 2015; 16(7):685–7. https://doi.org/10.1038/ni.3209 PMID: 26086136.